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Nalzi Yalcinkaya, Petri Urvil, Tor Savidge, Carolyn A. Bell, Oonagh Bodin, Jen Wood, Ashley E. Franks ,
Joel C. Bornstein , and Elisa L. Hill-Yardin
Gastrointestinal (GI) problems constitute an important comorbidity in many patients with autism. Multiple mutations in
the neuroligin family of synaptic adhesion molecules are implicated in autism, however whether they are expressed and
impact GI function via changes in the enteric nervous system is unknown. We report the GI symptoms of two brothers
with autism and an R451C mutation in Nlgn3 encoding the synaptic adhesion protein, neuroligin-3. We conﬁrm the
presence of an array of synaptic genes in the murine GI tract and investigate the impact of impaired synaptic protein
expression in mice carrying the human neuroligin-3 R451C missense mutation (NL3R451C). Assessing in vivo gut dysfunc-
tion, we report faster small intestinal transit in NL3R451C compared to wild-type mice. Using an ex vivo colonic motility
assay, we show increased sensitivity to GABAA receptor modulation in NL3
R451C mice, a well-established Central Nervous
System (CNS) feature associated with this mutation. We further show increased numbers of small intestine myenteric
neurons in NL3R451C mice. Although we observed altered sensitivity to GABAA receptor modulators in the colon, there
was no change in colonic neuronal numbers including the number of GABA-immunoreactive myenteric neurons. We fur-
ther identiﬁed altered fecal microbial communities in NL3R451C mice. These results suggest that the R451C mutation
affects small intestinal and colonic function and alter neuronal numbers in the small intestine as well as impact fecal
microbes. Our ﬁndings identify a novel GI phenotype associated with the R451C mutation and highlight NL3R451C mice
as a useful preclinical model of GI dysfunction in autism. Autism Res 2019, 12: 1043–1056. © 2019 The Authors. Autism
Research published by International Society for Autism Research published by Wiley Periodicals, Inc.
Lay Summary: People with autism commonly experience gastrointestinal problems, however the cause is unknown. We
report gut symptoms in patients with the autism-associated R451C mutation encoding the neuroligin-3 protein. We
show that many of the genes implicated in autism are expressed in mouse gut. The neuroligin-3 R451C mutation alters
the enteric nervous system, causes gastrointestinal dysfunction, and disrupts gut microbe populations in mice. Gut
dysfunction in autism could be due to mutations that affect neuronal communication.
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental
disorder diagnosed by impaired social communication
with restrictive and/or repetitive behaviors (APA DSM-5,
2013). As many as 90% of people with autism exhibit
gastrointestinal (GI) dysfunction including bloating,
abdominal pain, and alternating diarrhea and constipation,
which can exacerbate core autism traits [Buie et al., 2010;
McElhanon, McCracken, Karpen, & Sharp, 2014]. These
effects can subsequently reduce quality of life, for example,
via restricting access to health and education services. Many
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gene mutations affecting neuronal communication via
synapses are implicated in autism [Betancur, Sakurai, &
Buxbaum, 2009; Bourgeron, 2009; Cristino et al., 2014;
Jamain et al., 2003; Sudhof, 2008; Yan et al., 2005; Zhang
et al., 2009]. These mutations include genes encoding
neuroligins, a group of four postsynaptic adhesion mole-
cules (neuroligins-1 to 4) and their extracellular and intra-
cellular binding partners, neurexins and SHANK3 [Sudhof,
2008]. Expression of genes encoding several of these pro-
teins is reported in the GI tract [Wang et al., 2017, 2013;
Yang et al., 2014; Zhang et al., 2013]; however a systematic
analysis of expression in both the small and large intestine
and, of particular interest, in neuronal enriched samples is
needed.
To assess the role of this synaptic adhesion network in
autism-associated GI dysfunction, we elected to study a
well characterized mutation in neuroligin-3 [Jamain et al.,
2003]. The neuroligin-3 R451C missense mutation was ﬁrst
identiﬁed in two siblings diagnosed with autism [Jamain
et al., 2003].However, clinical information regardingGI func-
tion in these siblings has not previously been reported.
The effects of this mutation on brain function and behav-
ior have been extensively studied in mice. Multiple studies
have shown altered central nervous system (CNS) activity
[Etherton et al., 2011; Foldy, Malenka, & Sudhof, 2013;
Rothwell et al., 2014; Speed, Masiulis, Gibson, & Powell,
2015; Tabuchi et al., 2007]. NL3R451C mice are a well-
established model of autism that demonstrate impairments
relevant to core diagnostic traits including impairments
in social interaction and increased repetitive behaviors
[Burrows et al., 2015; Etherton et al., 2011; Hosie et al.,
2018; Tabuchi et al., 2007]. Despite this extensive charac-
terization, no detailed investigations into GI function in
NL3R451C mice have been undertaken.
GI motility and secretion are regulated by the enteric
nervous system (ENS), and to a large extent, indepen-
dently of the brain (reviewed in Hu & Spencer, 2018).
The ENS contains a complex network of neuronal sub-
populations deﬁned by morphology, function, and neu-
rochemistry (see Furness, 2012, for review) and hence is
often referred to as the “mini brain.” These neurons sense
chemical and mechanical stimuli and activate smooth
muscle contractility. The enteric neuronal network is
organized into two interconnected layers (the myenteric
and submucosal neuronal plexuses), which extend along
the length of the GI tract. The submucosal component
predominantly regulates the secretion of ﬂuids and elec-
trolytes, and the myenteric plexus mainly regulates GI
motility. Since GI dysfunction is common in the autism
population, we investigated whether the peripheral ner-
vous system is affected.
Microbes residing in the GI tract regulate mood and
behavior via the microbiota-gut-brain axis [Cryan &
O’Mahony, 2011; Foster & McVey Neufeld, 2013]. Several
studies have shown altered microbial signatures in ASD
patient populations [Luna et al., 2017; Mayer et al., 2014]
and report dysbiosis in rodent models demonstrating ASD
relevant behaviors [de Theije et al., 2014; Hsiao et al., 2013;
Sgritta et al., 2019]. We therefore assessed whether GI dys-
function could potentially impact the structure and func-
tion of fecal microbes in NL3R451C mice.
Changes in GI motility have been associated with altered
neuronal numbers in the myenteric plexus in other mouse
models [Margolis et al., 2016]. Here, we characterized GI
motility in the small intestine in vivo in wild-type (WT) and
NL3R451C mice. We additionally exploited an ex vivo motil-
ity approach [Roberts, Bornstein, Bergner, & Young, 2008;
Swaminathan et al., 2016] in the large intestine to assess for
subtle changes in GI neurotransmitter pathways in NL3R451C
mice. We further assessed for changes in neuronal subpopu-
lations in the myenteric plexus in this model. We propose
that the NL3R451C mutation affects synaptic signaling and
neuronal numbers in the ENS to causeGI dysfunction.
Methods
Clinical Data
The participation of the brothers was approved by the
ethics committee of the University of Gothenburg,
Sweden (Ref. Ö 586-99). After description of the study to
the subjects and their family, written informed consent
was obtained.
Animals
B6;129-Nlgn3tm1Sud/J mice were obtained from Jackson
Laboratories (Bar Harbor, ME, USA) and maintained to
generation F9 on a hybrid Sv129/C57Bl6 background.
NL3R451C and WT animals were derived by mating het-
erozygous females with NL3R451C males, which produced
50:50 WT and NL3R451C male offspring (Y/+ and Y/R451C)
and genotyped as described [Tabuchi et al., 2007]. Experi-
mental animals were weaned at 4 weeks of age and housed
in groups of four or ﬁve per cage with food and water avail-
able ad libitum. Similarly, for microbial experiments, mice
were housed in mixed genotype groups in individually ven-
tilated cages. The holding room was maintained on a
12:12 hr light/dark cycle with lights on at 7 a.m. and at an
ambient temperature of 20  1C. All procedures were
approved by The University of Melbourne Animal Ethics
Committee (AEC1613864-1, AEC1513519, AEC1312805.1).
Adult WT C57/Bl6 male mice aged 8–12 weeks used for
RT-PCR experiments assessing for presence of synaptic genes
in neuronal and mucosal enriched samples were obtained
from theAnimal ResourceCentre, Perth,WA, Australia.
Reverse Transcription-PCR
Expression of neuroligins and neurexins in preparations
of myenteric plexus with attached longitudinal muscle
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(LMMP) was assessed using RT-PCR with intron-spanning
speciﬁc primer pairs designed from full-length sequences
of mouse neuroligin and neurexin genes (Supplementary
Table S1). LMMP preparations were obtained from adult
WT C57/Bl6 male mice aged 8–12 weeks via microdis-
section to remove the mucosal, submucosal, and circum-
ferential muscle layers. Restriction enzyme sites were added
to the 50 end of most primers. Total RNA was isolated from
gut and brain tissues and homogenized in 1 mL of TRI
Reagent (Ambion; Applied Biosystems) [Neal, Parry, &
Bornstein, 2009]. RNA pellets were air dried and resuspended
in RNAsecure™ resuspension solution (Ambion). RNA con-
centrations weremeasured using aNanoDropND-1000 Spec-
trophotometer (Biolab) and resuspended RNAwas incubated
with 1 U DNase I (Ambion) at 37C for 20 min to remove
genomicDNAbefore cDNA synthesis. First strand cDNA syn-
thesis used Superscript III (Life Technologies) with 1 μg
total RNA in a 20 μL reaction mix and random hexamers
(0.5 μg μL−1; Bioline) according to the manufacturer’s
instructions. RT-PCR was performed in MyCycler™ PCR
machines (BioRad). Each 25 μL reaction mix consisted of
12.5 μL GoTaq GreenMaster Mix (Promega), 10 μL nuclease-
free water, 1 μL of forward and reverse primer (10 μM), and
1 μL cDNA template. The PCR conditions were: 1 cycle
(85C, 5min) and then 40 cycles (94C, 30 sec, 58C, 1min)
with a ﬁnal extension at 72C for 10min. PCR products were
resolved by gel electrophoresis, using HyperLadder IV
(Bioline, Fig. 1) to estimate PCR product size. To identify the
presence of the R451C mutation in mouse GI tract, ileal tis-
sue samples (including the full thickness of the GI wall) were
obtained from two WT and two NL3R451C 8 week old male
mice. Primers used were as reported previously [Tabuchi
et al., 2007]. In brief, the PCR conditions were: 1 cycle (95C,
1 min) and then 35 cycles (95C for 15 sec, 55C for 15 sec,
and 72C for 10 sec) andheld at 4C.
Small Intestinal Motility
Eight weeks old NL3R451C and WT mice were fed 0.2 mL
Carmine red dye (20 mg/mL, Sigma) by oral gavage. The
mice were culled after 10 min by cervical dislocation at
the same time of day to avoid circadian variation and the gut
removed. Parameters recorded weremaximumdistance trav-
eled by the dye (dye front) along the small intestine, animal
weight, small intestine length, and stomach weight. A ratio
of the distance traveled by the dye front relevant to the total
small intestine length was then calculated to remove poten-
tial bias due to inter animal variability in intestine length.
GI Motility Experiments
Adult male NL3R451C and WT mice (25–35 g; 8–12 weeks of
age) were euthanized by cervical dislocation. The entire
colon (~5 cm in length) was dissected, ﬂushed, and cannu-
lated in an organ bath superfused with physiological saline
(at 37C, 95%O2/5% CO2, ﬂow: 5 mL min
−1). After a
30 min equilibration, video recordings were acquired using
a Logitech Quickcam pro 9000 camera (30 fps, 640 × 840
resolution) in order to measure contractile motor activity
for a duration of 3 hr. Motor activity was recorded at base-
line (1 hr), with bath-applied antagonist (1 hr), and during
washout (1 hr). Pseudocolored spatiotemporal maps of
Figure 1. Expression of neuroligins and their binding partners in the GI tract. (a) Nlgn3 is expressed in large and small intestine of
mouse: neuroligin (Nlgn) 1–3 and neurexin (Nrxn) 1 and 2 mRNA is expressed in the myenteric plexus with associated smooth muscle
(MP), but little or no expression in mucosa (M) of colon or duodenum. Gapdh (Glyceraldehyde 3-phosphate dehydrogenase) serves as a
reference gene. RT-, no reverse transcriptase; +, brain positive control; NTC, no template water control. Gels were cropped horizontally
to improve clarity and conciseness of presentation. (b) The R451C mutation in Nlgn3 is present in the gastrointestinal tract of adult
mutant mice. Ileal samples from two WT and two NL3R451C mice show bands at the expected size showing a 40 bp shift due to
neocassette insertion [Tabuchi et al., 2007].
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motor patterns were created and motor pattern frequencies
were quantiﬁed using in-house software [Neal et al., 2009;
Swaminathan et al., 2016] (Fig. S1). Bicuculline (10 μM,
Tocris), gabazine (10 μM, Sigma), and CGP 54626 (100 nM,
Tocris) were diluted in saline.
Immunohistochemistry
Tissue from 8 to 12 weeks old male WT and NL3R451C mice
was emptied of fecal content, cut longitudinally along the
mesenteric border, stretched, and pinned in sylgard (Dow
Corning, Midland, MI, USA) lined petri dishes in phosphate
buffered saline (PBS) containing 1.25 μmol/L nicardipine
(Sigma Aldrich, Castle Hill, NSW, Australia). Every effort was
made to apply a consistent amount of stretch (longitudinal
and circumferential) between preparations. The tissue was
then ﬁxed using 4% paraformaldehyde at room temperature
(RT) for 80 min followed by 3 × 10 min washes with PBS.
Preparations of LMMP were obtained via microdissection to
remove the mucosal, submucosal, and circumferential mus-
cle layers.
LMMP preparations were exposed to 0.1% Triton
(ProSciTech, Thuringowa, QLD, Australia) and 10% CAS
block (Invitrogen; VIC, Australia) solution for 30 min at RT
and then incubated with primary antisera; human anti Hu
(1:5000; a pan neuronal marker, a gift from Dr. V. Lennon,
Mayo Clinic, USA), rabbit anti GABA (1:1000; Sigma-Aldrich,
Castle Hill, Australia), and sheep anti neuronal nitric oxide
synthase (nNOS) (1:1000; Jackson, West Grove, USA) for
24 hr at 4C andwashed (3 × 10min) in PBS. Theywere then
incubated with a secondary antisera (donkey anti human
Alexa 594; 1:750, Jackson Immunoresearch, West Grove, PA,
USA, and donkey anti rabbit Cy5; 1:100, Life Technologies
Carlsbad, CA, USA) at RT for 2.5 hr, washed in PBS
(3 × 10 min), and mounted on glass slides using ﬂuores-
cencemountingmedium (Dako Australia Pty. Ltd; Botany,
NSW, Australia).
Z-stack images were acquired using a confocal laser scan-
ningmicroscope (Zeiss ﬂuorescencemicroscope; Gladesville,
NSW, Australia) using a 20× objective (at 512 × 512 pixels
resolution, each image corresponded to an area of tissue
measuring 392.8 × 392.8 μm). All neurons stained for the
pan neuronal marker Hu, NOS, and GABA were visualized
using LSM software (version 4.2) and counted using ImageJ
software (NIH, Bethesda, MD, USA).
Jejunum. Approximately 5 cm of proximal jejunum tis-
sue was removed. For consistency, the proximal jejunum
was identiﬁed as the region located 5–6 cm anal to the
stomach-duodenal junction. To calculate the number of
nNOS neurons in the proximal jejunum, ten randomly
chosen ganglia from ﬁve WT and ﬁve NL3R451C mice were
selected and Hu and NOS labeled cells were counted. The
proportion of Hu cells that were nNOS-IR was subse-
quently determined.
Colon. Isolated colon was removed from between the cae-
cum and anus. Proximal colon preparations were obtained
from the striated region adjacent to the caecum.Mid colon
preparations were obtained from an area immediately
adjacent to the striated region of the proximal colon. Dis-
tal colon preparations were collected from an area 2 cm
from the most anal end of the preparation. The density of
enteric ganglia differs between colonic regions; therefore
different methods were used to count neurons in an unbi-
asedmanner in each region. For each preparation of proxi-
mal colon, seven images encompassing the total tissue
region (total area of 1.08 mm2) were obtained. For each
preparation of mid colon, 16 images encompassing the
total tissue region (total area of 2.46 mm2) were obtained.
These values were normalized to compare the numbers of
neurons per mm2 in the proximal and mid colon. In the
distal colon (where ganglia were more sparsely distrib-
uted), nonconsecutive images of 20 ganglia were acquired
for analysis. Neurons were considered to be in a separate
ganglion if they were separated from a neighboring neu-
ron by at least two cell body lengths [Neal et al., 2009]. To
calculate neuron density in proximal and mid colon, cell
counts were divided by the areas from which they were
obtained.
GI Microbial Community Analysis
Fecal samples were collected from ﬁve male mice expressing
the Nlgn3 R451C mutation and four WT age-matched
mice. Mice were isolated for 1 hr in sterilized non-ventilated
(“open topped”) cages containing no bedding at 5 and
9 weeks of age, and fecal samples were collected. DNA was
extracted from individual samples using the PowerSoil™
DNA isolation kit (MO-BIO Laboratories, Inc., CA, USA) as
per the manufacturer’s instructions for community ﬁnger-
printing by automated ribosomal intergenic spacer analysis
(ARISA) and next-generation sequencing. Fresh fecal sam-
ples were used for community-level physiological proﬁling
(CLPP). Detailed methods for ARISA, deep sequencing,
CLPP, and statistical analyses are described in the Supple-
mentaryMethods.
Statistical Analysis
Small intestinal transit. The ratio of maximum dis-
tance traveled by the dye front divided by total SI length,
the SI length, stomach, and animal weight were com-
pared individually using the Student’s t-test.
Colonic motility. There was no prior estimate of colonic
migrating motor complex (CMMC) frequencies available
for the WT controls, thus no power analysis was con-
ducted. CMMC frequency is a count variable and Poisson
regression is appropriate for analysis of these data. A hier-
archical Poisson regression model that accounts for the
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effect of multiple test days was used to estimate the effect
size, measured as the ratio of expected number of CMMCs.
Due to the absence of time effect, the frequencies were sub-
sequently summarized over control and drug periods. Due
to non-normality in the distribution, CMMC frequencies
between WT and NL3R451C mice under control conditions
and when treated with (a) bicuculline, (b) gabazine, and
(c) CGP 54626 were compared using the Wilcoxon–
Mann–Whitney rank-sum test, and corresponding effect
sizes were estimated using the Hodges–Lehman median
difference estimator. For analysis of CMMCs from
NL3R451C and WT mice, a large data set including control
data from experiments addressing other questions was
used. All CMMC frequency analyses were implemented
using STATA (version 12 IC) software. The two-sided sig-
niﬁcance threshold for each of the comparisons was set
at 0.05. A formal interaction test of these data was not
sufﬁciently powered due to the nature of the experi-
ments. Speciﬁcally, it was not ethically feasible to con-
duct the number of experiments required to sufﬁciently
increase analytical power to test for a genotype treatment
interaction. No correction for multiple comparisons in
the course of CMMC frequency data analysis was under-
taken due to the independent nature of the comparisons.
Jejunum neuronal densities. Statistical analyses for
cell counts in all intestinal regions were conducted using
Graph pad Prism (version 5.04) software. The number of
Hu and NOS immunoreactive neurons per ganglia were
compared individually using the nonparametric Mann–
Whitney U (two-tailed) test.
Colonic neuronal densities. Neuronal densities in
colonic regions were obtained by counting neurons immu-
noreactive for the pan neuronal marker Hu. Due tomorpho-
logical differences observed between the distal and other
colonic regions, data are reported as the normalized mean
number of cells per square millimeter of proximal and mid
colonic regions and the mean number of cells per ganglion
in the distal colon. For the proximal and mid colonic
regions, a two-way repeated measures ANOVA was utilized
to compare differences in neuronal densities between geno-
types (WT and NL3R451C). In order to eliminate false posi-
tives, a Bonferroni correction for multiple comparisons was
applied. An unpaired Student’s t-test was conducted to
examine differences in the mean number of neurons per
ganglion in the distal colon ofWT and NL3R451C mice.
The percentage of GABA neurons was examined between
genotypes and colonic regions and reported as the mean
percentage of Hu immunoreactive cells. Statistical compari-
sons were made between genotypes (WT and NL3R451C)
and colonic regions (proximal, mid, and distal) using two-
way repeated measures ANOVA with Bonferroni correction
for multiple comparisons.
Results
Although clinical diagnostic information regarding the orig-
inal siblings identiﬁed with the R451C mutation was previ-
ously reported [Jamain et al., 2003], critical clinical data
contained in the patient case notes regarding GI function
were omitted. As previously reported, both siblings were
assessed using the Vineland and WISC questionnaires and
met full criteria for autism (DSM-IV). The eldest brother
showed diarrhea and fecal incontinence, post-meal regurgi-
tation and esophageal inﬂammation. The younger brother
also had diarrhea, chronic intestinal pain, and signiﬁcantly
delayed bladder and bowel control. The speciﬁc detail of
these symptoms is described in Supplementary Note S1. In
summary, we report here that the patients expressing the
R451C mutation present with oesophageal regurgitation,
diarrhea, and chronic gut pain, which raise the question as
to whether this mutation is associated with GI dysfunction.
To clarify potential mechanisms underlying GI dysfunc-
tion in neuroligin-3 linked autism, we characterized expres-
sion of neuroligins and their binding partners, the neurexins,
in the mouse GI tract. Neuroligins and neurexins are
expressed in the rodent [Leembruggen et al., 2019; Wang
et al., 2017] and human [Wang et al., 2013; Yang et al., 2014;
Zhang et al., 2013] GI tract; however, little is known about
the functional contribution of neuroligin-3 expression in the
GI tract. Nlgn1, Nlgn2, Nlgn3, Nrxn1, and Nrxn2 mRNAs are
predominantly expressed inmyenteric plexus-enrichedprep-
arations of both duodenum and colon (Fig. 1a, Supplemen-
tary Fig. S2, Supplementary Table S1). RT-PCR analysis using
primers speciﬁc for the NL3R451C construct shows that this
mutation is indeed expressed in theGI tract ofNL3R451Cmice
(Fig. 1b, Supplementary Fig. S3, Supplementary Table S1).
It is unknown whether the R451C mutation affects GI
function in freely moving animals. Speciﬁcally, no analyses
of small intestinal function or enteric neuronal numbers
have been reported in this model. Therefore, to ascertain if
NL3R451C mice exhibit altered GI function in vivo, we mea-
sured small intestinal transit times [Machholz, Mulder, Ruiz,
Corning, & Pritchett-Corning, 2012]. Carmine red dye
(20 mg/mL) was administered to adult male WT and
NL3R451C mice by oral gavage, and the distance that the dye
front traveled along the small intestine was measured. The
small intestinal transit protocol was designed such that the
dye frontwould be located between the stomach and caecum
to reduce variability in transit time that might occur due to
the duration taken for content tomove through the caecum.
We observed faster small intestinal transit in NL3R451C com-
pared to WT mice. In NL3R451C mice, the dye front:small
intestinal length ratio was higher compared to WT litter-
mates (ratio of the dye front distance:total small intestinal
length; 0.46  0.03, 0.58  0.04; n = 17 and 18, WT and
NL3R451C, respectively; P = 0.01) (Fig. 2a). NL3R451C and WT
mice showed similar small intestinal length (40.8  3.1 and
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39.1  3.9 cm, WT and NL3R451C, respectively, P = 0.11),
stomach weight (0.40  0.04 and 0.44  0.04 g, WT and
NL3R451C, respectively, P = 0.41), and total body weight
(28.1  0.7 and 27.1  0.6 g,WT andNL3R451C, respectively,
P = 0.3) (Fig. 2b–d).
Previously, we showed that the NL3R451C mutation
decreases colonic motility in response to the serotonergic
receptor antagonist, tropisetron compared to WT mice
[Swaminathan et al., 2016]. Whether gut function is
changed due to altered neural function involving GABA
neurotransmission as reported in the brain of these mice
[Etherton et al., 2011; Tabuchi et al., 2007] is unknown.
The use of the video-imaging assay to quantify changes
in colonic motility is well established for examining ENS
function [Balasuriya, Hill-Yardin, Gershon, & Bornstein,
2016; Roberts et al., 2008; Swaminathan et al., 2016]. This
approach takes advantage of the fact that when mouse
colon is isolated from the CNS and maintained ex vivo,
enteric neural activity drives a stereotyped repetitive motor
pattern, the CMMC (Fig. S1). Under these conditions, the tis-
sue is isolated from all extrinsic inﬂuences including both
central input and circulating hormones [Spencer, Dinning,
Brookes, & Costa, 2016]. Neuronal subtypes within the
ENS underlying CMMCs include intrinsic sensory neu-
rons, interneurons, secretomotor, excitatory, and inhibi-
tory motor neurons [Gwynne & Bornstein, 2007] and
can be pharmacologically perturbed to reveal functional
impairments. In contrast with our small intestinal in vivo
ﬁndings, under control conditions, CMMC frequency was
identical in WT and NL3R451C tissues demonstrating simi-
lar enteric neural baseline activity in the ex vivo colon
(Fig. 3a,e,i).
In the brain, the NL3R451C mutation alters inhibitory and
excitatory activity at the synapse. Speciﬁcally, NL3R451C
mice show increased sensitivity to locally applied GABA in
brain slices [Tabuchi et al., 2007] and altered GABAergic
inhibitory activity [Etherton et al., 2011; Foldy et al., 2013;
Pizzarelli & Cherubini, 2013; Tabuchi et al., 2007]. We
therefore aimed to assess if GABAergic signaling at GABAA
receptors alters colonic motility in the mouse ENS in the
presence of the R451C mutation, similar to previous reports
of altered neural activity in the brain of these mice. To assess
for changes in enteric GABAergic neurotransmission, we
recorded CMMCs in isolated colons challenged by exposure
to the GABAA receptor antagonists bicuculline or gabazine.
Under these conditions, NL3R451C colons exhibited signiﬁ-
cantly reduced motility (i.e., failure to extend CMMCs along
the length of the colon) in the presence of either bicuculline
or gabazine compared with WT colons (Fig. 3b,c,f,g,j,k; Sup-
plementary Video S1). In contrast, CMMC numbers were
unaffected by the GABAB receptor antagonist CGP 54626
(Fig. 3d,h,l) indicating that a GABAA receptor speciﬁc mech-
anism is involved.
To understand the mechanism underlying the altered
small intestinal transit and colonic motility, we assessed
for changes in total neuronal numbers and proportions
of neuronal populations in the mouse myenteric plexus.
Using immunoﬂuorescence, myenteric neurons in the
colon and small intestine were stained for expression of
the pan neuronal marker, Hu. Additionally, neurons in
the colon were labeled for GABA. Because GABA is mini-
mally expressed in the mouse small intestine [Sang &
Young, 1996], we instead chose to investigate for changes in
cells expressing themajor inhibitory neurotransmitter in the
ENS; nitric oxide, using an antiserum targeting its synthesiz-
ing enzyme, nNOS. Using this approach, we compared
inhibitory neuronal numbers in the proximal jejunum
of WT and NL3R451C mice. Interestingly, NL3R451C mice
showed a 30% increase in the number of myenteric neurons
(Hu+ cells) per ganglion in the proximal jejunum (mean
number of Hu+ cells/ganglion; WT: 22  2, NL3R451C:
32  3; P = 0.032, Mann–Whitney U test; ﬁve animals in
both groups; Fig. 4a–c). The total number of immunoreactive
nNOS+ neurons per ganglion in the proximal jejunum was
also greater in NL3R451C mice (8  2) compared withWT lit-
termates (5  1; P = 0.015, Mann–Whitney U test; ﬁve ani-
mals in both groups, Fig. 4d–f). Accordingly, there was a
greater percentage ofmyenteric neurons immunoreactive for
nNOS in NL3R451C mice (28.4  1%) compared with WT
(23.7  0.8%, P = 0.013; unpaired Student’s t-test; ﬁve WT
andﬁveNL3R451Cmice).
Perturbations in neurotransmitter levels during enteric
development can lead to changes in both neuronal
Figure 2. Faster small intestinal transit in NL3R451C mice. (a) Small
intestinal (SI) transit is increased in the NL3R451C mice (n = 17 WT,
n = 18 NL3; P = 0.01). No difference in (b) SI length (n = 17 WT, n = 22
NL3; P = 0.11), (c) stomach weight (n = 16 WT, n = 18 NL3; P = 0.41), or
(d) body weight (n = 16 WT, n = 21 NL3; P = 0.30). *P < 0.05.
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numbers and proportion of GABAergic neurons, along
with signiﬁcant disturbances in colonic motility [Li et al.,
2011]. However, we found that overall neuronal numbers
in the colon myenteric plexus did not differ substantially
between NL3R415C and WT mice nor did the proportion
of neurons immunoreactive for GABA in the proximal,
mid, and distal colon (Fig. 5a–g). Overall, there were no
differences in total neuronal number between genotypes
(P = 0.91). Total (Hu labeled) neuronal numbers were sim-
ilar in WT and NL3R451C proximal colon (WT: 317.1 and
NL3R451C: 315.3 cells/mm2; CI: −128.3 to 124.5; n = 3
mice per group) and mid colon (WT: 314.0 and NL3R451C:
305.8 cells/mm2; CI: −134.6 to 118.2). The percentage of
neurons immunoreactive for GABA was similar between
genotypes (WT: 12% and NL3R451C: 10%; CI: −10.2 to 6.5;
n = 3 mice per group) and mid colon (WT: 16.8% and
NL3R451C: 3.5%; CI: −4.9 to 11.8). In a regional analysis,
the percentage of GABA neurons was higher in distal com-
pared with proximal-to-mid colonic regions (P < 0.0001).
To assess if fecal microbes were altered in NL3R451C
mice, we used community ﬁngerprinting (ARISA) and
next generation sequencing of fecal DNA as well as mea-
sures of carbon substrate utilization in fresh fecal samples
fromWT andmutant mice over time (i.e., at 5 and 9 weeks
of age). We found that the R451C mutation predomi-
nantly altered the structure and function of the microbial
community at 5 and 9 weeks of age, respectively.
Using ARISA proﬁling, we revealed operational taxo-
nomic units (OTUs; used as a proxy for microbial species)
unique to genotype groups and differences in microbial
community structure between WT and NL3R451C samples,
even when mice were cohoused. A total of 12 and 6 OTUs
unique to WT and NL3R451C mice, respectively, were
detected at 5 weeks of age, equating to 23% and 14% of
their total microbial populations (Fig. 6a). Unique OTUs
were classiﬁed as those present in all NL3R451C samples
but absent from all WT analyses, and vice versa. At
9 weeks, the number of unique OTUs decreased to 1 and
2 in samples from WT and NL3R451C mice, respectively,
equating to less than 5% of the overall microbial
populations in both genotypes (Fig. 6b). We detected sig-
niﬁcant grouping of microbial communities between
5-week-old WT and NL3R451C mice using nonmetric mul-
tidimensional scaling (global R = 0.503, P < 0.01; Fig. 6c)
but this genotype segregation was no longer present at
9 weeks of age (Fig. 6d). Age was a driving factor of overall
Figure 3. NL3R451C mice show GABAA-mediated GI dysfunction ex vivo. (a–l) GABAA antagonists decrease CMMCs in NL3
R451C compared to WT
colonic preparations. CMMC frequency is depressed by GABAA antagonists; spatiotemporal maps showing CMMC frequency in colonic preparations
from WT (a–d) and NL3R451C (e–h) mice under control (con) conditions (a,e) and in the presence of antagonists for GABAA (bicuculline (bic),
10 μM, (b,f); gabazine (gab), 10 μM, (c,g) and GABAB (CGP 54626 [CGP], 100 nM, (d,h) receptors. (i) NL3R451C and WT CMMC frequency from a
large control dataset (NL3R451C [n = 70] and WT mice [n = 69]) was unchanged. The median number of CMMCs per 1 hr recording period in con-
trol conditions was 4 in both WT (95% CI: 1, 11) and NL3R451C (95% CI: 1, 15) mice (median difference 1, 95% CI −2, 4; P = 0.509).
(j) Bicuculline treatment reduced the median number of contractions for NL3R451C (n = 16) compared with WT (n = 16) mice (median difference:
6 contractions, 95% CI: 1, 12; P = 0.03; Supplementary Video S1). (k) Gabazine (10 μM) also reduced the median number of contractions in
NL3R451C (n = 11) compared to WT (n = 11) mice (median difference: 5 CMMCs, 95% CI: 2, 9; P = 0.009). (l) CGP had no effect in WT (n = 8) and
NL3R451C (n = 9) mice (median difference: −1 CMMC, 95% CI: −9, 6; P = 0.809). *P < 0.05; **P < 0.01.
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Figure 4. Increase in Hu and NOS myenteric neurons per ganglia in proximal jejunum. Confocal images of Hu (red) and nitric oxide
synthase (NOS; green) staining in proximal jejunum of (a) WT and (b) NL3R451C adult mice. Co-stained cells are yellow. (c) Density of
Hu+ cells in the proximal jejunum of WT and NL3R451C mice (P = 0.032; n = 5 WT, n = 5 NL3R451C). (d,e) Confocal images of nNOS (green)
in adult mouse proximal jejunum. (f) Density of nNOS neurons per ganglion (P = 0.016 n = 5 WT, 5 NL3R451C mice). Box plots represent
median interquartile range and range of the data. *P < 0.05, obtained by Mann–Whitney U test (two-tailed). Scale bar represents
50 μm; scanning area = 393.56 μm × 393.56 μm.
Figure 5. Colonic GABA neuronal numbers are unaffected by the R451C mutation. There was no change in total neuronal number or
neuronal proportions immunoreactive for GABA in NL3R451C (n = 3) compared to WT (n = 3) colon; representative images of myenteric
plexus of (a–c) WT and (d–f) NL3R451C distal colon illustrating neurons immunoreactive for Hu (a,d; red) and GABA (b,e; green) and mer-
ged images (c,f). Arrows indicate neurons labeled for Hu and GABA. Scale bar in (d) represents 100 μm. (g) Pie graphs indicate the per-
centage of Hu-positive neurons immunoreactive for GABA in WT and NL3R451C proximal, mid, and distal colonic regions. The percentage
of GABA neurons was higher in distal compared with proximal-to-mid colonic regions (P < 0.0001) in both WT and NL3R451C mice.
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Figure 6. Structural and functional changes of the NL3R451C gut microbial community. The effect of genotype on fecal microbial communities at
5 and 9 weeks of age. Venn diagram of common and unique OTUs within the WT and NL3R451C at 5 (a) and 9 (b) weeks of age. Nonmetric multi-
dimensional scaling ordinations of ARISA generated microbial communities at 5 (c) and 9 weeks of age (d). Signiﬁcant grouping was observed
between WT and NL3R451C at 5 weeks of age (P < 0.01). Dashed line showing genotype effect; decreasing stress values indicate increasing good-
ness of ﬁt. (e) Average abundances of bacterial phyla in WT and NL3R451C mice at 5 and 9 weeks of age. The average portion of Firmicutes in WT
mice increased from 67.67% at 5 weeks of age to 71.82% at 9 weeks of age. This was accompanied by a decrease in Bacteroidetes from 26.63% at
5 weeks of age to 22.50% at 9 weeks of age. A similar trend in NL3R451C microbial communities was observed over time. Firmicutes increased from
68.46% to 70.43% between 5 and 9 weeks of age and Bacteroidetes decreased from 25.94% to 23.54% between ages. (f) Functional richness was
decreased in both WT and NL3R451C mice at 9 weeks compared to 5 weeks of age (P < 0.01). Error bars represent SEM. Mean utilization of (g) car-
boxylic acids (h) amino acid carbon substrates by microbial communities in WT and NL3R451C mice at 5 and 9 weeks of age was derived from Biolog
EcoPlates data. Between 5 and 9 weeks of age, carboxylic acid glucosaminic acid utilization was decreased in WT communities (paired t(3) = 11,
P < 0.01). Error bars represent SEM. *P < 0.05, **P < 0.01 level. § indicates marginal signiﬁcance (P = 0.07).
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microbial community structure regardless of genotype
(global R = 0.435, P < 0.001; Fig. S4a,b). Microbial richness
(i.e., the total number of OTUs) was unchanged between
genotypes or across time (week 5: 43.2  3 and 51.3  7,
week 9: 42.3  4 and 48.2  4; NL3R451C and WT mice;
mean OTU numbers  SEM, respectively).
We next identiﬁed bacterial phyla and determined their
relative abundance in microbial communities of WT and
NL3R451C mice using next-generation sequencing (Illumina)
techniques (Supplementary Methods). At 5 and 9 weeks of
age, Firmicutes and Bacteroidetes equated to on average
93% of the overall abundance in microbial communities.
Proteobacteria accounted for 3% of the total abundance
while Actinobacteria, Candidate, Cyanobacteria, and
Tenericutes comprised 4% (Fig. 6e). To identify key OTUs
driving dissimilarity between WT and NL3R451C microbial
communities as seen by ARISA analyses, we used similar-
ity percentage (SIMPER) analysis to calculate the contribu-
tion of each species to the dissimilarity between each of
the groups (Supplementary Methods). At 5 weeks of age,
we identiﬁed OTUs (and their respective assigned taxa)
contributing to the top 20% of dissimilarity in bacterial
communities (Table 1). We identiﬁed 4 of the 20 OTUs at
5 weeks of age as likely to be good discriminators of geno-
type. Threeof theseOTUsbelonged to thephylumFirmicutes,
class Clostridia (OTUs 145, 170, and 386), while OTU
172 belonged to the Candidate phyla. Althoughwe identiﬁed
no differences in the diversity of microbes present in the WT
and NL3R451C community structure at 9 weeks of age, six
OTUs had altered abundance between genotypes (Table S2).
In addition to genotype-speciﬁc differences, the cage environ-
ment inﬂuenced microbial proﬁles (15 and 17 OTUs contrib-
uted to housing dissimilarity at 5 and 9 weeks, respectively;
Tables S3 and S4).
We also analyzed functional proﬁles in WT and NL3R451C
feces using a carbon source utilization assay (Supplementary
Methods) and showed that microbial communities differed
in individual carbon substrate utilization both with geno-
type and age. Metabolic rates of carbon source usage were
determined using the average well-color development of
Biolog EcoPlates containing fresh fecal microbes during
74 hr. Although functional richness, deﬁned as the number
of different carbon sources the community could utilize,
was similarly decreased in both WT and NL3R451C mice
from 5 to 9 weeks of age (P < 0.01; Fig. 6f), biological mecha-
nisms differed between the genotypes as NL3R451C samples
showed higher utilization of glucosaminic acid (paired
t(5.29) = 3.31, P < 0.05) comparedwithWT samples at 9weeks
of age (Fig. 6g). No differences in polymer or amide/amine
utilizationwere seen (Fig. S4e,f). At 9 weeks, NL3R451Cmicro-
bial communities had a marginally signiﬁcant decrease in
utilization of the carbohydrate i-Erythritol (paired t(4) = 2.36,
P < 0.077; Fig. S4g) compared toWT. Mouse age was a driver
of microbial function (global R = 0.705, P < 0.001; Fig. S4a,b)
Table 1. Taxon Contribution to Genotype Dissimilarity in Mouse Microbial Communities at 5 Weeks
Average abundance (%)
Individual contribution (%) Cumulative contribution (%)Taxon OTU −97% WT NL3R451C Diss/SD
Bacteroidetes; Bacteroidiaa† 71 6.3 3.2 1.3 1.60 1.60
Firmicutes; Lachnospiraceae 145b 3.0 6.9 1.4 1.40 3.00
Bacteroidetes; Prevotellaceae 108 7.0 4.4 1.3 1.30 4.30
Firmicutes; Lachnospiraceae 332 4.0 2.6 1.1 1.10 5.40
Firmicutes; Ruminococcaceae 278 3.9 2.2 1.2 1.10 6.40
Firmicutes; Lachnospiraceae 170b 3.6 4.8 1.4 1.10 7.50
Firmicutes; Lachnospiraceae 395 3.6 3.3 1.2 1.00 8.50
Firmicutes; Lachnospiraceae 137 2.9 3.2 1.2 1.00 9.50
Firmicutes; Lachnospiraceae 94 7.0 4.5 1.2 1.00 10.60
Firmicutes; Lachnospiraceae 1711 3.5 3.7 1.2 1.00 11.60
Firmicutes; Lachnospiraceae 31 7.1 8.3 1.1 1.00 12.50
Firmicutes; Lachnospiraceae 384 3.4 2.4 1.1 0.90 13.50
Firmicutes; Lachnospiraceae 97 8.6 6.0 1.1 0.90 14.40
Candidatea§ 172b 6.6 5.8 1.5 0.90 15.30
Firmicutes; Lachnospiraceae 314 3.1 3.6 1.2 0.90 16.20
Firmicutes; Lachnospiraceae 203 2.9 2.4 1.1 0.90 17.10
Firmicutes; Lachnospiraceae 386b 1.2 3.7 1.9 0.90 18.00
Firmicutes; Lachnospiraceae 169 5.4 5.9 1.0 0.90 18.80
Firmicutes; Ruminococcaceae 310 3.0 3.0 1.2 0.80 19.70
Firmicutes; Lachnospiraceae 141 6.2 6.2 1.3 0.80 20.50
Key Diss/SD positive 0.00–1.19 1.20–1.39 1.40–1.59 1.60–1.79 1.80–1.99
Key Diss/SD negative 0.00–1.19 1.20–1.39 1.40–1.59 1.60–1.79 1.80–1.99
Notes: Taxa are given at the phylum and family level. Diss, dissimilarity; SD, standard deviation; WT, wild-type.
aTaxa given to the highest available classiﬁcation (reference OTU has been classiﬁed to the §phylum and †class level only).
bIndicates likely good discriminators between genotypes (Diss/SD ≥1.4). The highest abundance value in each case is indicated in bold (green =
increased in NL3R451C mice, red = decreased in NL3R451C mice).
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and although utilization of individual carbon sources dif-
fered, overall metabolic proﬁles were similar between WT
and NL3R451C mice (Fig. S4c,d). In addition, both WT and
NL3R451C samples showed a marginally signiﬁcant decrease
in amino acid L-phenylalanine utilization (paired t(4) = 2.45,
P = 0.07; Fig. 6h) at 9weeks.
Overall, these results identifyGI dysfunction in patients and
mice expressing the NL3R451C mutation. Data in mice high-
light altered small intestinal transit in vivo but no change in
colonic activity ex vivounder control conditions.However,we
observed a subtle dysmotility phenotype mediated by GABAA
receptors in the colon. In agreement with the clear functional
changes in the small intestine, myenteric neuronal numbers
in the NL3R451C mouse jejunum were signiﬁcantly increased
whereas neuronal numbers in the colonwere unchanged. Sub-
tle changes in the structure and function ofmicrobial commu-
nitieswere also detected in fecal samples fromNL3R451Cmice.
Discussion
These ﬁndings indicate a potential biological basis for the GI
symptoms frequently reported by people with autism.
Although the effects of the R451C mutation are well studied
in the mouse brain, here we highlight the case history of
brothers with autism, conﬁrming the presence of GI related
problems in patients with the NL3R451C genetic mutation.
By verifying expression of Nlgn3 in the mouse GI tract, our
ﬁndings support the idea that neuroligin-3 plays a role in GI
function. Furthermore, expression of neurexin–neuroligin
pathway genes in the gut suggests that ENS dysfunction may
be a common feature across a range of autism genotypes.
We identiﬁed an in vivo GI phenotype and increased neu-
ronal numbers in the small intestine of the NL3R451C mouse
model of autism. How this change in neuronal circuitry
affects segmentation and mixing of small intestinal content
is unknown.However, segmentation can slowdown the pro-
gression of chyme along the small intestine due to its role in
bidirectional mixing of content. An increased in the number
of NOS immunoreactive neurons and subsequent release of
the inhibitory neurotransmitter NO could inhibit segmenta-
tion. It is therefore possible that an increased density of jeju-
nalmyenteric neurons increases small intestinalmotility.
There was no difference in baseline colonic motility or
myenteric neuronal numbers in NL3R451C and WT mice.
However, we identiﬁed a subtle GI phenotype showing
increased sensitivity of GABAA receptors, mirroring previous
ﬁndings in the brain. Speciﬁcally, the NL3R451C mice show
reduced colonicmotility in the presence of theGABAA recep-
tor antagonists gabazine and bicuculline. It should be noted
that bicuculline also acts as an antagonist for nicotinic recep-
tors [Demuro, Palma, Eusebi, & Miledi, 2001] and therefore
this receptor pathway could be altered in the NL3R451Cmice.
To rule out actions of bicuculline on nAChR as a potential
mechanism underlying the decreased CMMC frequency in
NL3R451C colon, we used another GABAA-speciﬁc antago-
nist (gabazine) with a different pharmacological proﬁle
including interaction with glycine receptors and not
nAChR. Although it is clear that GABA is not a major neu-
rotransmitter in the ENS, these functional data suggest
that in the NL3R451C colon dysregulation of GABAergic
activity may occur. Multiple studies have demonstrated that
the R451Cmutation causes alterations inCNS synaptic func-
tion including GABA neurotransmission in mice. Regional
speciﬁc changes in neural activity in the hippocampus,
cerebral cortex, the amygdala, and the striatum have been
reported in theNL3R451Cmousemodel using neurophysio-
logical techniques [Etherton et al., 2011; Foldy et al., 2013;
Hosie et al., 2018; Rothwell et al., 2014; Speed et al.,
2015; Tabuchi et al., 2007]. NL3R451C mice display altered
GABAergic transmission in somatosensory cortical slices
[Tabuchi et al., 2007] and the hippocampus [Foldy et al.,
2013; Pizzarelli & Cherubini, 2013]. A recurrent theme is
an imbalance of excitatory and inhibitory neurotransmis-
sion in brain tissue, which likely contributes to core behav-
iors in autism. Our ﬁndings suggest that an imbalance in
neural activitymay also occur in the GI tract.
GABA labeling is sparse in the small intestine but is
found in a subset of interneurons and motor neurons in
mouse colon [Li et al., 2011; Sang & Young, 1996]. GABA
has also been implicated in enteric synaptic transmission
[Krantis, 2000] by a depolarizing action on myenteric neu-
rons [Cherubini & North, 1984]. Because NL3R451C mice
showed similar numbers of GABA immunoreactive neurons
in the proximal, mid, and distal colon, the increased sensi-
tivity to GABAA receptor modulators in NL3
R451C mice is
likely due to altered numbers and or composition of GABAA
receptors in the colon. We cannot exclude the known
action of bicuculline to act as a nicotinic receptor antago-
nist however, and that bicuculline could act to more
potently suppress CMMCs in the mutant than controls.
Although there are multiple validated genetic mouse
models of autism available, little is known regarding GI
dysfunction in these models. A recent report showed GI
microbial changes in SHANK3 knockout mice [Sgritta et al.,
2019], however whether mutations in the neuroligin–
neurexin–shank network affect GI motility in mice is
unknown. Here, we provide the ﬁrst evidence that the
autism-associated NL3R451C gene mutation produces altered
small intestinal transit and a GABAA receptor mediated
change in colonicmotility, via an effect in the ENS. Although
the precise role of GABA acting via GABAA receptors to inﬂu-
ence colonic motility is unclear, a recent study showed that
GABAA receptor subunits are instrumental in conferring
inﬂammatory responses to psychological stress in rodents
[Seiﬁ, Rodaway, Rudolph, & Swinny, 2018]. GABA-mediated
alterations in GI motility are also highly relevant to patients
with autism, who are commonly prescribed a range of medi-
cations such as benzodiazepines which modulate GABAergic
pathways in the brain to treat anxiety, agitation, nervousness,
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and sleep disorders [Self, Hale, & Crumrine, 2010]. Because
diazepam potentiates GABA effects on single myenteric neu-
rons [Bertrand&Galligan, 1992],GABAactions canbemodu-
lated at the level of the ENS. AsmanyASDpatients exhibit GI
symptoms [McElhanon et al., 2014], further investigation of
the effects ofGABAmodulators onGI function iswarranted.
Taken together, the microbiome ﬁndings suggest that
the R451C mutation affects the gut microbiota. Impor-
tantly, microbiota from NL3R451C mice had an increased
ability to utilize the organic compound glucosaminic acid
as a carbon source indicating a gut dysbiosis. As shown in
physically separated C57BL/6 mice, a divergence in the
fecal associated microbial populations can lead to changes
in the abundance of amino acids and short chain fatty acids
in the gut [Rogers et al., 2014]. An increased ability to utilize
carbon sources by the NL3R451C microbial population may
indicate changes to the metabolic proﬁle available in the GI
tract. These changes may be physiologically relevant
because if the fecal population is capable of consuming a
broader range of organic compounds, these components
will potentially be removed and no longer available in the
GI system of the NL3R451C mice.
While dysbiosis might result from alterations in the
brain–gut axis, we speculate that the perturbed ENS in
NL3R451C mice has a local effect on the microbiota. Altered
distribution of the microbiota may contribute to changes
in the community, perhaps secondary to GI dysmotility.
The exact mechanism underlying this effect, either via
structural and functional changes of the gut, the microbial
community, or a feedback mechanism between them,
requires further investigation and will provide information
about GI dysfunction in autism.
In summary, the R451C mutation is associated with GI
dysfunction in autism, in NL3R451C mice, and in colon iso-
lated from these mice. We propose that mutations in genes
encoding synaptic proteins such as neuroligins are likely to
result in ENS dysfunction and associated GI symptoms in
autism. Importantly, our data suggest GABAA receptors as a
potential therapeutic target for treatment of autism-
associated GI symptoms. The observation of GI dysfunction
further conﬁrms the validity of the NL3R451C mouse model,
a useful preclinical tool to unravel the impact of altered syn-
aptic activity in GI disorders in autism. Identifying the GI
effects of this rare mutation could have broader implica-
tions for understanding multiple autism-associated muta-
tions affecting this important transsynaptic pathway. Our
ﬁndings provide new insights into mechanisms mediating
the intrinsic synaptic origins of autism-associated GI disease
and point to the need for rigorous assessment of peripheral
causes of GI symptoms in autism patients.
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